869550-68-5Relevant articles and documents
HCV NS3 protease inhibitors
-
, (2016/06/01)
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
HCV NS3 PROTEASE INHIBITORS
-
, (2013/06/05)
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
FUSED HETEROCYCLIC COMPOUNDS
-
, (2008/06/13)
There is provided a CRF receptor antagonist comprising a compound of the formula (I) : wherein R1 is an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano
Synthesis and pharmacological studies at the Gly/NMDA, AMPA and Kainate receptors of new oxazolo[4,5-c]quinolin-4-one derivatives bearing different substituents at position-2 and on the fused benzo ring
Calabri, Francesca Romana,Colotta, Vittoria,Catarzi, Daniela,Varano, Flavia,Lenzi, Ombretta,Filacchioni, Guido,Costagli, Chiara,Galli, Alessandro
, p. 897 - 907 (2007/10/03)
The synthesis and biological evaluation at the Gly/NMDA, AMPA and Kainate receptors of new oxazolo[4,5-c]quinolin-4-one derivatives are reported. Different substituents were introduced at the 2-position (mercapto, carbonyl and methyl groups) and on the fu